{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-190147","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.929130+00:00","generated_at":"2026-06-13T05:39:29.562592+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B","bullets":["Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.","Highest dose (1,200 mg) showed non-statistically significant 16% reduction in protocol-defined influenza A illness vs placebo.","Secondary endpoint (CDC-defined ILI) showed 57% reduction, but not statistically significant (95% CI -2.51 to 82.15).","VIR-2482 was generally well tolerated; no safety signals identified; ~3,000 participants enrolled.","Cash, cash equivalents and investments were approximately $1.9 billion as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-190147","json":"https://secwatch.observer/filing/0001193125-23-190147.json","markdown":"https://secwatch.observer/filing/0001193125-23-190147.md","text":"https://secwatch.observer/filing/0001193125-23-190147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/0001193125-23-190147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/d517183d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:39:29.562592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6daf87065dd1225acf800bf64785c9546a8101cc","claim":"Vir Biotechnology, Inc. reported preliminary financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Although it has not finalized its full financial results for the quarter ended June 30, 2023, Vir Biotechnology, Inc. (the “Company”) disclosed in a press release on July 20, 2023, that it had cash, cash equivalents and investments of approximately $1.9 billion as of June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/0001193125-23-190147-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}